Aggressive Fibromatosis: Clinical Aspects

Česká verzia

Authors: Z. Hlavatá; Š. Porsok
Authors place of work: Oddelenie klinickej onkológie, Národný onkologický ústav, Bratislava, Slovenská republika
Published in the journal: Klin Onkol 2012; 25(2): 91-96
Category: Přehledy

Summary

The clinical picture of desmoids is unpredictable, which is a feature of different tumor specific associations. Anatomic location, age, sex, association with FAP as well as other factors determine biological behavior of the tumor. Negative prognosis is linked with the intraabdominal area and as many as 80% of desmoids are associated with FAP. Currently, biological targeting therapy is used in the treatment of many cancer diseases. It is only the question of time when and by which of these therapies we will be able to treat the patients with aggressive fibromatosis as well. A disadvantage is heterogenity and rare occurrence of desmoids. The efficacy of tailoring treatment still depends on knowledge and study of particular disease biological markers, which is currently the most important issue.

Key words:
aggressive fibromatosis – risk factors – treatment

The authors declare they have no potential conflicts of interest concerning drugs, products, or services used in the study.

The Editorial Board declares that the manuscript met the ICMJE “uniform requirements” for biomedical papers.

Submitted:
16. 8. 2011

Accepted:
19. 2. 2012

Zdroje

1. Bertario L, Russo A, Sala P et al. Genotype and phenotype factors as determinants of desmoid tumors in patients with familial adenomatous polyposis. Int J Cancer 2001; 95(2): 102–107.

2. Clark SK, Phillips RK. Desmoids in familial adenomatous polyposis. Br J Surg 1996; 83(11): 1494–1504.

3. Durno C, Monga N, Bapat B et al. Does early colectomy increase desmoid risk in familial adenomatous polyposis? Clin Gastroenterol Hepatol 2007; 5(10): 1190–1194.

4. Nieuwenhuis MH, De Vos Tot Nederveen Cappel W, Botma A et al. Desmoid tumors in a dutch cohort of patients with familial adenomatous polyposis. Clin Gastroenterol Hepatol 2008; 6(2): 215–219.

5. Sturt NJ, Gallagher MC, Bassett P et al. Evidence for genetic predisposition to desmoid tumours in familial adenomatous polyposis independent of the germline APC mutation. Gut 2004; 53(12): 1832–1836.

6. Church JM, McGannon E. Prior pregnancy ameliorates the course of intra-abdominal desmoid tumors in patients with familial adenomatous polyposis. Dis Colon Rectum 2000; 43(4): 445–450.

7. Sturt NJ, Clark SK. Current ideas in desmoid tumours. Fam Cancer 2006; 5(3): 275–285.

8. Church J, Berk T, Boman BM et al. Collaborative Group of the Americas on Inherited Colorectal Cancer. Staging intra-abdominal desmoid tumors in familial adenomatous polyposis: a search for a uniform approach to a troubling disease. Dis Colon Rectum 2005; 48(8): 1528–1534.

9. Godwin Y, McCulloch TA, Sully L. Extra-abdominal desmoid tumour of the breast: review of the primary management and the implications for breast reconstruction. Br J Plast Surg 2001; 54(3): 268–271.

10. Clark SK, Neale KF, Landgrebe JC et al. Desmoid tumours complicating familial adenomatous polyposis. Br J Surg 1999; 86(9): 1185–1189.

11. Nuyttens JJ, Rust PF, Thomas CR Jr et al. Surgery versus radiation therapy for patients with aggressive fibromatosis or desmoid tumors: a comparative review of 22 articles. Cancer 2000; 88(7): 1517–1523.

12. Schulz-Ertner D, Zierhut D, Mende U et al. The role of radiation therapy in the management of desmoid tumors. Strahlenther Onkol 2002; 178(2): 78–83.

13. Ballo MT, Zagars GK, Pollack A et al. Desmoid tumor: prognostic factors and outcome after surgery, radiation therapy, or combined surgery and radiation therapy. J Clin Oncol 1999; 17(1): 158–167.

14. Gronchi A, Casali PG, Mariani L et al. Quality of surgery and outcome in extra-abdominal aggressive fibromatosis: a series of patients surgically treated at a single institution. J Clin Oncol 2003; 21(7): 1390–1397.

15. Spear MA, Jennings LC, Mankin HJ et al. Individualizing management of aggressive fibromatoses. Int J Radiat Oncol Biol Phys 1998; 40(3): 637–645.

16. Janinis J, Patriki M, Vini L et al. The pharmacological treatment of aggressive fibromatosis: a systematic review. Ann Oncol 2003; 14(2): 181–190.

17. Lim CL, Walker MJ, Mehta RR et al. Estrogen and antiestrogen binding sites in desmoid tumors. Eur J Cancer Clin Oncol 1986; 22(5): 583–587.

18. Tonelli F, Valanzano R, Brandi ML. Pharmacologic treatment of desmoid tumors in familial adenomatous polyposis: results of an in vitro study. Surgery 1994; 115(4): 473–479.

19. Lipschutz A, Jadrijevitc D, Girardi S et al. Antifibromatogenic potency of 9-fluoro derivates of progesterone. Nature 1956; 178(4547): 1396–1397.

20. Lanari A. Effect of progesterone on desmoid tumors (aggressive fibromatosis). N Engl J Med 1983; 309(24): 1523.

21. Wilcken N, Tattersall MH. Endocrine therapy for desmoid tumors. Cancer 1991; 68(6): 1384–1388.

22. Brooks MD, Ebbs SR, Colletta AA et al. Desmoid tumors treated with triphenylethylenes. Eur J Cancer 1992; 28A(6–7): 1014–1018.

23. Häyry P, Reitamo JJ, Vihko R et al. The desmoid tumor. III. A biochemical and genetic analysis. Am J Clin Pathol 1982; 77(6): 681–685.

24. Tsukada K, Church JM, Jagelman DJ et al. Noncytotoxic therapy for intra-abdominal desmoid tumor in patients with familial adenomatous polyposis. Dis Colon Rectum 1992; 35(1): 29–33.

25. Ali IU. Celecoxib reduces sporadic colorectal adenomas: Result from the Adenoma Prevention with Celecoxib (APC) trial. 97th Annual Meeting of the American Association for Cancer Research April 2006. Abstract CP-3.

26. Grosser T, Fries S, FitzGerald GA. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Invest 2006; 116(1): 4–15.

27. Lindor NM, Dozois R, Nelson H et al. Desmoid tumors in familial adenomatous polyposis: a pilot project evaluating efficacy of treatment with pirfenidone. Am J Gastroenterol 2003; 98(8): 1868–1874.

28. Geurs F, Kok TC. Regression of a great abdominal desmoid tumor by interferon-α. J Clin Gastroenterol 1993; 16(3): 264–265.

29. Fernberg JO, Brosjö O, Larsson O et al. Interferon-induced remission in aggressive fibromatosis of the lower extremity. Acta Oncol 1999; 38(7): 971–972.

30. Stengel G, Metze D, Dörflinger B et al. Treatment of extra-abdominal aggressive fibromatosis with pegylated interferon. J Am Acad Dermatol 2008; 59 (2 Suppl 1): S7–S9.

31. Gega M, Yanagi H, Yoshikawa R et al. Successful chemotherapeutic modality of doxorubicin plus dacarbazine for the treatment of desmoid tumors in association with familial adenomatous polyposis. J Clin Oncol 2006; 24(1): 11–12.

32. Al-Otaibi ML, Turcotte RE, Hings I et al. Low-dose chemotherapy for extra-abdominal desmoid tumor. Saudi Med J 2008; 29(12): 1730–1734.

33. Bertagnolli MM, Morgan JA, Fletcher CD et al. Multimodality treatment of mesenteric desmoid tumours. Eur J Cancer 2008; 44(16): 2404–2410.

34. Ioannou M, Demertzis N, Iakovidou I et al. The role of imatinib mesylate in adjuvant therapy of extra-abdominal desmoid tumors. Anticancer Res 2007; 27(2): 1143–1147.

35. Mace J, Sybil Biermann J, Sondak V et al. Response of extraabdominal desmoid tumors to therapy with imatinib mesylate. Cancer 2002; 95(11): 2373–2379.

36. Wcislo G, Szarlej-Wcislo K, Szczylik C. Control of aggressive fibromatosis by treatment with imatinib mesylate. A case report and review of the literature. J Cancer Res Clin Oncol 2007; 133(8): 533–538.

37. Gounder MM, Lefkowitz RA, Keohan ML et al. Activity of Sorafenib against desmoid tumor/deep fibromatosis. Clin Cancer Res 2011; 17(12): 4082–4090.